Gaurav Kulkarni
Psychiatry · Jefferson City, MONPI 1962714162
Payments from drug & device makers
Across 195 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$619
- Otsuka America Pharmaceutical, Inc.$587
- AbbVie$470
- Johnson & Johnson$425
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$309
- Indivior Inc.$217
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,697100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 22 | $619 |
| Otsuka America Pharmaceutical, Inc. | 32 | $587 |
| AbbVie(2 entities) | 30 | $470 |
| Johnson & Johnson | 23 | $425 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $309 |
| Indivior Inc. | 13 | $217 |
| Neurocrine Biosciences, Inc. | 13 | $214 |
| Teva Pharmaceuticals USA, Inc. | 9 | $202 |
| Sunovion Pharmaceuticals Inc. | 11 | $160 |
| Gilead | 1 | $104 |
| Lundbeck LLC | 5 | $65 |
| Corium, LLC | 4 | $57 |
| Avanir Pharmaceuticals, Inc. | 4 | $56 |
| Shire North American Group Inc | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $41 |
| Ironshore Pharmaceuticals Inc. | 2 | $32 |
| MDD US Operations, LLC | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Orexo US, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$461
- ABILIFY ASIMTUFII$102
- ABILIFY MAINTENA$102
How this compares
$3,714 in reported general payments places this provider in the 80th percentile of 680 psychiatry providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 70 | $11,554 |
| Methylphenidate Hcl | 22 | $707 |
| Bethanechol Chloride | 16 | $520 |
| Quetiapine Fumarate | 31 | $365 |
| Divalproex Sodium | 11 | $324 |
| Fenofibrate | 16 | $307 |
| Trazodone Hcl | 40 | $244 |
| Hydroxyzine Hcl | 15 | $237 |
| Buprenorphine Hcl | 11 | $226 |
| Buspirone Hcl | 22 | $208 |
| Mirtazapine | 18 | $201 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $193 |
| Metoprolol Succinate | 16 | $184 |
| Duloxetine Hcl | 22 | $158 |
| Paroxetine Hcl | 25 | $147 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Jefferson City
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Franco SicuroOlivette$2.3M
- Howard IlivickySaint Charles$2.1M
- Vadim BaramSaint Louis$1.9M
- Gary LinkerFordland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.